Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MHLW Issues Manufacturing, Marketing Approval For E Keppra To UCB
UCB said that it is expected to market Levetiracetam as E Keppra in Japan. Levetiracetam was developed by UCB, which is now marketed as Keppra in around 90
UCB said that it is expected to market Levetiracetam as E Keppra in Japan. Levetiracetam was developed by UCB, which is now marketed as Keppra in around 90
The affected lot/code being recalled is 101408. The product was sold to distributors and retail stores across the US through internet sales. FDA advises that the product poses
SENSE is an ongoing multi-center, open-label, double-blind, controlled Phase 2b trial designed to show differences in the incidence of treatment-related neuropsychiatric events in treatment-naive patients with no evidence
Earlier, in 2005, Abraxis had entered into a license agreement with Taiho Pharma, under which Taiho Pharma got the right to market Abraxane in Japan. Taiho Pharma has
CSKI said that the internal R&D team of the company has developed the drug based on registration standards of similar imported drugs. CSKI claimed that the drug’s main
Sandoz said that its Enoxaparin has been developed under an agreement signed between Momenta Pharma and Sandoz. Enoxaparin is therapeutically equivalent to the reference-listed drug, Lovenox, which is
Glenmark’s Norethindrone tablets are a progestin-only oral contraceptive indicated for the prevention of pregnancy. It works by suppressing ovulation, thickening cervical mucus to prevent sperm penetration, and altering
Akebia is expected to recruit up to 28 patients in AKB-6548 Phase 2a study, to assess the safety, tolerability and pharmacokinetics of a single dose of AKB-6548 in
The vaccine has been developed to prevent or delay the recurrence sarcoma at Memorial Sloan-Kettering Cancer Center (MSKCC) where preclinical and early clinical development completed in 2009. MabVax
Tibotec said that TMC278 is an investigational product, and the safety and efficacy has not yet been established. Echo (TMC278-TiDP6-C209) and Thrive (TMC278-TiDP6-C215) are pivotal Phase 3, double-blind,